Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 154 participants.

Also called NCT05193578

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 154 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05193578
Other papers using this trial's data
  • Semaglutide Treatment of Antipsychotic-Treated Patients With Schizophrenia, Prediabetes, and Obesity: The HISTORI Randomized Clinical Trial JAMA psychiatry, 2025-11-01 DOI, PubMed 40900607, PMC12409653 Not in the PMC Open Access subset.

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Denmark (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT05193578. Randomized; quadruple masking; primary purpose treatment. Start 2022-01-01 (actual); primary completion 2024-03-18 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Home-based Intervention With Semaglutide Treatment Of Neuroleptica-Related Prediabetes
Acronym
HISTORI
Condition
Schizophrenia
Condition
Prediabetic State
Intervention (Drug)
Semaglutide, 1.34 mg/mL
Intervention (Other)
Placebo
Lead sponsor
Jan Frystyk (class: other)
Collaborator
Region Zealand (class: other)
Collaborator
Region of Southern Denmark (class: other)
Collaborator
Steno Diabetes Center Sjaelland (class: other government)
Collaborator
Steno Diabetes Center Odense (class: other)

Record details

Record id
cardio:ct-nct05193578
Content hash
05b29c5c36cb0c09a4805ddefea06758d10cd470ce95cdedd0991ea478a61c44